OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Perioperative Pembrolizumab or Placebo + Neoadjuvant Cisplatin and Gemcitabine in Muscle-Invasive Bladder Cancer: The Double-Blind, Phase 3 KEYNOTE-866 Study

@garysteinbergmd
@DrChrisHoimes

🔬 Phase 3, double-blind (n=907): perioperative pembrolizumab or placebo + neoadjuvant gemcitabine-cisplatin and RC + PLND in cisplatin-eligible MIBC. Primary endpoint: EFS.
➡️ Median EFS 74.1 mo vs NR; HR 0.88 (0.71–1.10); P=.1366
➡️ pCR 44.4% vs 35.8%; OS HR 1.00 (0.79–1.27); neither formally tested
➡️ Grade 3–5 TEAEs 80.2% vs 75.1%
✅ Perioperative pembrolizumab did not confer a statistically significant EFS benefit; safety profile manageable and consistent with prior reports. #BladderCancer

🎙️ Jens Bedke
👥 Arlene Siefker-Radtke · Gary Steinberg · Hiroyuki Nishiyama · Xiao Fang · Ritesh Kataria · Blanca Homet Moreno · Christopher Hoimes

(4Sight Made from Abstracts publicly available at the ESMO website)

Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper